ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Successful treatment of chronic Hepatitis C infection in Republic of Srpska

13th Euro-Global Gastroenterology Conference

Jelena Petkovic Dabic and Renata Tamburic

University Clinical Centre of the Republic of Srpska, Bosnia and HerzegovinaHealth Insurance Fund of the Republic of Srpska, Bosnia and Herzegovina

ScientificTracks Abstracts: J Gastrointest Dig Syst

DOI: 10.4172/2161-069X-C5-076

Abstract
Introduction: Viral hepatitis C remains one of the major health and social problems related to infectious diseases. Today, interferon-free therapy using new direct-acting antivirals (DAA) has increased the cure rate across different HCV-infected patient populations. Nowdays, viral hepatitis C threatens to become a healing disease. Methods: The methodolgy involved a retrospective study. We will present our experiences from the work carried out in 2016 and 2017. We have approved treatment with ombitsvir/paritaprevir/ritonavir + dasabuvir in a total of 55 patients' report. Results: In 2016, we analyzed 25 patients, 17 (68%) males and 8 (32%) females with age of 26-66 years. In 2017, we analyzed 30 patients, 22 (73%) males and 8 (26,7%) females with age of 23-67 years. Sustained viral response (SVR) is 100%. Adverse events are typically mild, most commonly consisting of fatigue, headache, nausea, and diarrhea. Discussion/Conclusions: The regimen consisting of ombitasvir/paritaprevir/ritonavir and dasabuvir is highly efficacious in the treatment of viral hepatits C. Today, viral hepatitis C is a curable disease, which reduces membrane damage, as well as the costs of treating patients. Recent Publications: 1. Zeuzem S et al. (2015) Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann. Intern. Med. 163(1):1-13. 2. Chahal H S et al. (2016) Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naïve population. JAMA Internal Medicine. 176(1):65-73. 3. Poordad F and Dieterich D (2012) Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J. Viral. Hepat. 19(7):449-464. 4. Manns M P et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 358(9286):958-965. 5. Ferenci P et al. (2014) ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 370(21):1983-1992.
Biography

Jelena Petkovic Dabic graduated from the Faculty of Medicine in University in Banja Luka Republic of Srpska, 2005. Experienced Head with a demonstrated history of working in the medical practice industry. She is skilled at Research Management, Medical Education, Healthcare, and Healthcare Management. Strong professional with a Doctor of Medicine (MD) master focused in Health/Health Care Administration/Management from School of Public Health Faculty of Medicine, University of Belgrade. She is currently employed as Head of the Health Sector in the Health Insurance Fund of the Republic of Serbia. She is currently planning the treatment for hepatitis C and all funded biological medicines. She is now Dermatovenerology Resident-University Clinical Center of the RS. She is mainly interested in new molecules and their application in the treatment of very serious illness.

E-mail: jelena.petkovic81@yahoo.com

 

Top